

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.

*This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement and the information herein does not constitute or form a part of any offer or solicitation to purchase, subscribe or sell securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), or the securities laws of any state of the United States or other jurisdiction. The securities referred to herein are being offered and sold outside the United States in reliance on Regulation S under the Securities Act (the “**Regulation S**”) and may not be offered or sold within the United States absent registration or an applicable exemption from registration under the Securities Act. No public offering of the securities referred to herein will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. No money, securities or other consideration is being solicited by this announcement or the information contained herein and, if sent in response to this announcement or the information contained herein, will not be accepted.*



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

(Bond Stock Code: 05818)

OVERSEAS REGULATORY ANNOUNCEMENT

This overseas regulatory announcement is issued by Luye Pharma Group Ltd. (the “**Company**”) pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited.

Reference is made to the announcements of the Company dated 3 June 2026 and 4 June 2026 in relation to the Concurrent Repurchase and issue of the Bonds (the “**Announcements**”). Unless otherwise defined, capitalised terms herein shall have the same meanings as those defined in the Announcements.

The Board would like to draw the attention of the Shareholders and potential investors to the attached announcement published on the website of the Vienna Stock Exchange on 8 June 2026, in relation to the approval by the Vienna Stock Exchange for the admittance to listing of, and trading in, the Bonds on the Vienna MTF operated by the Vienna Stock Exchange. The first trading day of the Bonds is expected to be on 10 June 2026.

Completion of the Concurrent Repurchase and the subscription and issuance of the Bonds is subject to the satisfaction and/or waiver of the conditions precedent contained in the Dealer Manager Agreement and the Subscription Agreement, as applicable. In addition, the Dealer Manager Agreement and the Subscription Agreement may be terminated under certain circumstances. Please refer to the sections headed “The Dealer Manager Agreement” and “Subscription Agreement” in the announcement of the Company dated 4 June 2026 for further information.

As the Concurrent Repurchase and the issue of the Bonds may or may not complete, Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 8 June 2026

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. HUANG Liming; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.

2371. Veröffentlichung

des Börseunternehmens Wiener Börse AG vom 08. Juni 2026



Listing Vienna MTF

First trading day: 10 June 2026

Issuer Details

Issuer	Luye Pharma Group Ltd
Listing of instruments on	Vienna Stock Exchange approved the securities for admittance to listing and trading on 04 June 2026

Securities

XS3389912588	USD 180,000,000 5.25% Convertible Bonds due 2031
--------------	--

XETRA Trading details

Trading system	XETRA® T7
Quotation type	Quotation in percentage
Quotation	Flat quotation (dirty price)
Trading procedure	Xetra Auction Only
XETRA® Market Group	BNQ8
CCP eligible	No
Market segment	corporates standard
Qualified Investor Segment	Yes

The requirements of the Stock Exchange Act regarding the formal admission of financial instruments to trading on a regulated market and the obligations of issuers on a regulated market do not apply to financial instruments traded on the Vienna MTF. However, the obligations defined in Article 17 (Public Disclosure of Inside Information), Article 18 (Insider Lists) and Article 19 (Managers' Transactions) of the Market Abuse Regulation (Regulation (EU) No. 596/2014) do apply in conjunction with § 155 para. 1 nos. 2 to 4 and § 119 para. 4 of the Austrian Stock Exchange Act 2018, as well as the bans imposed by Article 14 (Prohibition of Insider Dealing and of Unlawful Disclosure of Inside Information) and Article 15 (Prohibition of Market Manipulation) of the Market Abuse Regulation (Regulation (EU) No. 596/2014) in conjunction with §§ 154, § 163 and § 164 of the Austrian Stock Exchange Act 2018. However, the above mentioned obligations for financial instruments traded on the Vienna MTF are only applicable if the issuer has submitted an application for inclusion in trading of the financial instrument or has approved it. It is hereby pointed out that there may be differences with respect to financial instruments of foreign issuers trading on the Vienna MTF as compared to financial instruments of Austrian issuers included in the Vienna MTF. These differences may concern the following (this is not an exhaustive list): property law aspects (the rights of the buyer regarding financial instruments held in safe custody abroad, for example), the delivery or settlement of financial instruments, differences with respect to company law (e.g. voting rights and dividend rights) and also other aspects such as taxation.